Research map: Profile of People Living with HIV Switching Prior Antiretroviral Treatment to a Doravirine-Based Regimen in the Real-World Clinical Setting in Greece: The Retrospective DORAVITO Study

Back to the article

Papers in this map

  1. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies · Erik B von Elm · 2008 · 17695 citations · Cited by this paper
  2. Lipoprotein(a) as a Cardiovascular Risk Factor: Clinical Significance and Therapeutic Perspectives · 2026 · Related
  3. Future challenges for clinical care of an ageing population infected with HIV: a modelling study · Mikaëla Smit · 2015 · 947 citations · Cited by this paper
  4. Advancing Human Placental Modeling Through Stem-Cell-Derived Trophoblast Organoids and Reprogramming Innovations · 2026 · Related
  5. Guidelines for good pharmacoepidemiology practice (GPP) · Public Policy Committee, International Society of Pharmacoepidemiology · 2015 · 297 citations · Cited by this paper
  6. The Role of Endothelial–Mesenchymal Transition (EndMT) in Aneurysm Formation · 2026 · Related
  7. Fundamentals of Clinical Data Science · Pieter Kubben · 2018 · 238 citations · Cited by this paper
  8. Ectoine Inhibits IL-1β-Induced Inflammation by Suppressing the NF-κB Pathway in Chondrocytes and Alleviates Osteoarthritis in a Rat Model · 2026 · Related
  9. Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies · Adam Trickey · 2024 · 167 citations · Cited by this paper
  10. Differential Protective Actions of Dulaglutide and Dexamethasone in Methotrexate Induced Pulmonary Fibrosis: Relationship with AMPK and Beclin-1 Levels · 2026 · Related
  11. Comorbidity is more common and occurs earlier in persons living with HIV than in HIV-uninfected matched controls, aged 50 years and older: A cross-sectional study · Rafael Aguiar Maciel · 2018 · 158 citations · Cited by this paper
  12. Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: From Targeted Therapy and Combination Strategies to Emerging Therapies · 2026 · Related
  13. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial · Jean‐Michel Molina · 2018 · 150 citations · Cited by this paper
  14. Evaluation of Early and Delayed Meloxicam Treatment Against Regulated Cell Death Pathways and ERK1/2 Phosphorylation in a Rat Model of Renal Ischemia–Reperfusion Injury · 2026 · Related
  15. In Vitro Characterization of MK-1439, a Novel HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor · Ming‐Tain Lai · 2013 · 143 citations · Cited by this paper
  16. Overcoming mTOR Inhibitor Resistance: From Biological Basis to Therapeutic Strategies · 2026 · Related
  17. In Vitro Resistance Selection with Doravirine (MK-1439), a Novel Nonnucleoside Reverse Transcriptase Inhibitor with Distinct Mutation Development Pathways · Meizhen Feng · 2014 · 114 citations · Cited by this paper
  18. Region-Specific Proteomic Profiles of Extracellular Vesicles (EVs) Derived from Human Macular and Peripheral RPE-Choroid Explants · 2026 · Related
  19. Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial · Margaret Johnson · 2019 · 100 citations · Cited by this paper
  20. Bioactive Metabolites of Solanum tuberosum L. in Inflammation Modulation and Tissue Regeneration: A Scoping Review of Wound Healing Mechanisms · 2026 · Related
  21. Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations · Meizhen Feng · 2016 · 98 citations · Cited by this paper
  22. Non-AIDS-related comorbidities in people living with HIV-1 aged 50 years and older: The AGING POSITIVE study · Rosário Serrão · 2018 · 88 citations · Cited by this paper
  23. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial · Chloe M. Orkin · 2020 · 81 citations · Cited by this paper
  24. Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial · Princy N. Kumar · 2021 · 57 citations · Cited by this paper
  25. High prevalence of cardiovascular risk factors in adults living in Greece: the EMENO National Health Examination Survey · on behalf of the EMENO study group · 2020 · 51 citations · Cited by this paper
  26. Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development · Elizabeth Anne Martin · 2020 · 49 citations · Cited by this paper
  27. Cardiovascular risk factors in HIV infected individuals: Comparison with general adult control population in Greece · Giota Touloumi · 2020 · 46 citations · Cited by this paper
  28. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors · Gaetana Sterrantino · 2019 · 38 citations · Cited by this paper
  29. Real-life use of Doravirine in treatment-experienced people living with HIV: A multicenter Italian study · Maria Mazzitelli · 2022 · 38 citations · Cited by this paper
  30. Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients · Cathia Soulié · 2018 · 32 citations · Cited by this paper
  31. Real life use of dolutegravir doravirine dual regimen in experienced elderly PLWH with multiple comorbidities and on polypharmacy · Maria Mazzitelli · 2021 · 24 citations · Cited by this paper
  32. Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates · Ernest Asante‐Appiah · 2021 · 23 citations · Cited by this paper
  33. Prescribing issues in older adults living with HIV: thinking beyond drug–drug interactions with antiretroviral drugs · Françoise Livio · 2019 · 22 citations · Cited by this paper
  34. Real-Life Safety of Doravirine in Treatment-Experienced, Virologically Suppressed PLWHIV · Arturo Ciccullo · 2021 · 19 citations · Cited by this paper
  35. Doravirine/lamivudine/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: A real-life experience · Leonardo Calza · 2023 · 19 citations · Cited by this paper
  36. Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting · Paolo Maggi · 2023 · 18 citations · Cited by this paper
  37. Compliance with clinical guidelines and adherence to antiretroviral therapy among patients living with HIV · Neeta Tandon · 2018 · 17 citations · Cited by this paper
  38. The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations · Carlos Enrique Guerrero-Beltrán · 2020 · 16 citations · Cited by this paper
  39. Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus–1: An Integrated Safety Analysis · Melanie Ann Thompson · 2019 · 14 citations · Cited by this paper

Source: OpenAlex (CC0)